Physician profile
Den A Trumbull
NPI 1982783742
$1,427.62
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $192 · 2021: $257 · 2022: $181 · 2023: $323 · 2024: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $270.76 | 2020-2022 | |
| Corium, LLC | $205.89 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $128.10 | 2019-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Tris Pharma INC | $103.12 | 2019-2023 | Dyanavel Xr |
| Pfizer INC. | $95.39 | 2021-2024 | |
| Ironshore Pharmaceuticals INC. | $91.77 | 2019-2023 | Jornay Pm |
| Glaxosmithkline, LLC. | $88.31 | 2021-2022 | |
| Sanofi Pasteur INC. | $88.26 | 2021-2024 | |
| Adlon Therapeutics L.P. | $85.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $84.05 | 2023-2024 | Flumist Quadrivalent |
| Genentech USA, INC. | $57.07 | 2019-2023 | Xofluza |
| Shire North American Group INC | $54.13 | 2019 | |
| Sobi, INC | $46.47 | 2022-2023 | |
| Aytu Biopharma, INC. | $16.54 | 2020 | |
| Coloplast Corp | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Den Trumbull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.